Synergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds In Vitro-Reference-Cited by-同舟云学术

Synergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds In Vitro

Published:2017-04 Issue:4 Volume:61 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Li Wei¹,Sanchez-Hidalgo Andrea¹,Jones Victoria¹,de Moura Vinicius Calado Nogueira¹,North E. Jeffrey²,Jackson Mary¹

Affiliation:

1. Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA

2. Creighton University, School of Pharmacy & Health Professions, Department of Pharmacy Sciences, Omaha, Nebraska, USA

Abstract

ABSTRACT A number of inhibitors of the essential Mycobacterium tuberculosis mycolic acid transporter, MmpL3, are currently under development as potential novel antituberculosis agents. Using the checkerboard method to study the interaction profiles of various antituberculosis drugs or experimental compounds with two different chemotypes inhibiting this transporter (indolcarboxamides and adamantyl ureas), we showed that MmpL3 inhibitors act synergistically with rifampin, bedaquiline, clofazimine, and β-lactams.

Funder

NIH/NIAID

Global Alliance for TB Drug Development

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02399-16

Reference23 articles.

1. Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3

2. Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection